Erectile dysfunction: where are we going?

Journal of Men's Health and Gender

Volumn 3, Issue 4, 2006, Pages 323-325

  Eardley, Ian ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SLX 2101; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

AWARENESS; COMPREHENSION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; GENE THERAPY; HUMAN; MEDICAL PROFESSION; METABOLIC SYNDROME X; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PENIS; PENIS ERECTION; PHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PUBLIC HEALTH; RISK FACTOR; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SOCIAL SUPPORT; STEM CELL TRANSPLANTATION; SYMPTOM; URETHRA DISEASE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 33750796391     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2006.10.005     Document Type: Editorial

References (12)

1. Rosen R.C., Fisher W.A., Eardley I., Niederberger C., Nadel A., and Sand M. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 20 5 (2004) 607-617
2. Leriche R. Des obliterations arterielles hautes comme cause d'une insuffuissance circulatoire des members inferieures. Bull Soc Chir Paris 49 (1923) 1404
3. Kupelian V., Shabsigh R., Araujo A.B., O'Donnell A.B., and McKinlay J.B. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 176 1 (2006) 222-226
4. Thompson I.M., Tangen C.M., Goodman P.J., Probstfield J.L., Moinpour C.M., and Coltman C.A. Erectile dysfunction and subsequent cardiovascular disease. JAMA 294 23 (2005) 2996-3002
5. Salem A., Kendirci M., and Hellstrom W.J. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 7 7 (2006) 661-669
6. Kaufman J.M., and Dietrich J.W. Safety and efficacy of avanafil, a new phosphodiesterase type 4 inhibitor for treating erectile dysfunction. J Urol 174 Suppl 4 (2006) 299 (Abstract 923)
7. Prince W., Campbell A.S., Tong W., et al. SLX-2102, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol 174 Suppl 4 (2006) 299 (Abstract 924)
8. Hedlund P. PT-141 Palatin. Curr Opin Investig Drugs 5 4 (2004) 456-462
9. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med 1 (2004) 58-65
10. McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47 6 (2005) 838-845
11. Mulhall J.P., Land S., Parker M., et al. The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2 (2005) 532-542
12. Melman A., Bar-Chama N., McCullough A., Davies K., and Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 48 2 (2005) 314-318